slides · global inventory
Solution
Slide type collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 8,880
Current window 6,001-6,030
Pages 296
Rows per page 30
Slide type
6,001-6,030 of 8,880
28
The slide uses a four-column layout to explain the target, the molecule structure, the mechanism of action, and the current clinical status.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
31
The slide uses a biological pathway diagram and a bar chart to demonstrate efficacy.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
06
The diagram illustrates a biological signaling pathway with specific nodes highlighted as targets for the company's therapeutic approach.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Challenges in current cancer treatment and unmet needsLoop · Logic Chain1 hit
08
The slide uses a biological process diagram to map drug assets to specific protein targets.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Challenges in current cancer treatment and unmet needsLoop · Logic Chain1 hit
12
The kinome tree is a standard visualization for kinase selectivity.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Challenges in current cancer treatment and unmet needs1 hit
24
The slide uses a biological signaling pathway map to justify combination therapy strategy.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
26
The slide uses two tables to demonstrate competitive advantage in potency and pharmacokinetics.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
27
The diagram shows the signaling pathway with specific drug targets highlighted.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
38
The slide uses Western blot data to demonstrate potency and a table to demonstrate pharmacokinetic superiority.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
39
The chart is a Kaplan-Meier survival plot. The comparison shows ERAS-801 (blue line) outperforming standard EGFR inhibitors (Erlotinib, Lapatinib, Osimertinib) and vehicle control.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
48
The slide uses western blot data to demonstrate the superiority of ERAS-007 in a specific biological pathway context.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
55
The slide uses a biological pathway diagram to illustrate the mechanism of action.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
56
The slide contrasts intermittent high-coverage dosing (ERAS-007) with sustained steady-state coverage (ERAS-601) to manage efficacy vs. toxicity.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
08
The slide uses a hub-and-spoke style circular process diagram centered on a human silhouette.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
15
The slide uses a complex flow diagram combining a linear process with two internal feedback loops (Active Learning).Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
16
The slide uses a circular process flow to represent a proprietary R&D pipeline.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
20
The slide uses a circular flow diagram to represent the integration of AI and experimental biology.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
21
The diagram illustrates a flywheel-like process of data integration leading to novel targets.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
23
The slide illustrates a computational drug discovery workflow using MPO (Multiparameter Optimisation).Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
24
The diagram uses a hub-and-spoke model to show data integration, followed by a funnel for molecule generation and a circular feedback loop for active learning.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
26
The scatter plot highlights a specific cluster of 'active learning' selections that deviate from the standard Pareto frontier.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
29
Exscientia | Investor Presentation Deck | 76 slidesExscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
33
Includes a biological pathway diagram and a honeycomb diagram for indications.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
34
The slide uses a three-column layout to define technical constraints for drug development.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
38
The slide uses a heatmap to correlate '617 sensitivity with synergy outcomes for three different drug combinations.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
41
The slide showcases a successful asset development case study involving AI-driven design.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
43
The slide uses a process-oriented layout to explain the company's methodology.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
47
Includes a biological pathway diagram showing LSD1 interactions with various complexes and substrates.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
48
Includes a biological pathway diagram and supporting bullet points on therapeutic mechanism and safety profile.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
49
The slide uses a process flow diagram to explain the therapeutic mechanism and competitive advantage of the '539 molecule.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit